IRulya Therapeutics (IRLA) Capital Expenditures (2018 - 2025)
IRulya Therapeutics (IRLA) recorded Capital Expenditures of $4,000 in Q4 2025, down 97.0% from $133,000 a year earlier and down 94.6% from the prior quarter.
Powered by 
Analysis
IRulya Therapeutics (IRLA) Capital Expenditures (2018 - 2025) Analysis & Trends
For FY2025, IRulya Therapeutics reported Capital Expenditures of $352,000, up 37.0% from FY2024.
- Annual Capital Expenditures has increased for three straight years, with a five-year compound annual growth rate of 46.6% (FY2020 to FY2025).
- Across earlier years, Capital Expenditures came in at $257,000 in FY2024 (+60.6%), $160,000 in FY2023 (+20.3%), $133,000 in FY2022 (-26.1%) and $180,000 in FY2021 (+246.2%).
- The Q4 2025 figure is the lowest quarterly Capital Expenditures since Q2 2019.
- On a year-over-year basis, Capital Expenditures rose in four of the last six quarters, with growth averaging 141.5%.
- Peak year-over-year performance for Capital Expenditures in the last five years was growth of 640.0% in Q1 2021, against a decline of 97.0% in Q4 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $74,000 (Q3 2025), $126,000 (Q2 2025) and $148,000 (Q1 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,261.99 Bn | 1,235.61 Bn | 20.46 Bn | 3.18 Bn |
| 2 | Johnson & Johnson | 678.93 Bn | 598.79 Bn | 17.30 Bn | 1.36 Bn |
| 3 | AbbVie | 518.29 Bn | 486.30 Bn | 13.12 Bn | 301.00 Mn |
| 4 | Merck | 365.98 Bn | 328.92 Bn | 13.19 Bn | 1.04 Bn |
| 5 | Novartis Ag | 316.85 Bn | 290.09 Bn | - | - |
| 6 | Astrazeneca | 293.40 Bn | 267.29 Bn | 13.26 Bn | -3.30 Bn |
| 7 | Amgen | 251.78 Bn | 203.43 Bn | 7.58 Bn | 587.00 Mn |
| 8 | Gilead Sciences | 210.61 Bn | 185.71 Bn | 6.73 Bn | 237.00 Mn |
| 9 | Pfizer | 166.87 Bn | 114.23 Bn | 12.56 Bn | 573.00 Mn |
| 10 | IRulya Therapeutics | 207.35 Mn | 91.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 4,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 126,000.00 |
| Mar 31, 2025 | 148,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 39,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Mar 31, 2023 | 136,000.00 |
| Dec 31, 2022 | 78,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Mar 31, 2022 | 5,000.00 |
| Dec 31, 2021 | 44,000.00 |
| Jun 30, 2021 | 99,000.00 |
| Mar 31, 2021 | 37,000.00 |
| Dec 31, 2020 | 10,000.00 |
| Sep 30, 2020 | 20,000.00 |
| Jun 30, 2020 | 17,000.00 |
| Mar 31, 2020 | 5,000.00 |
API Access
IRulya Therapeutics Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IRLA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "IRLA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IRLA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();